A
Andrea Decensi
Researcher at University of Genoa
Publications - 92
Citations - 4483
Andrea Decensi is an academic researcher from University of Genoa. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 28, co-authored 92 publications receiving 4038 citations. Previous affiliations of Andrea Decensi include Westmead Hospital & Ente Ospedaliero Ospedali Galliera.
Papers
More filters
Journal ArticleDOI
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
Andrea Decensi,Matteo Puntoni,Pamela J. Goodwin,Massimiliano Cazzaniga,Alessandra Gennari,Bernardo Bonanni,Sara Gandini +6 more
TL;DR: A comprehensive literature search and meta-analysis of epidemiologic studies to assess the effect of metformin on cancer incidence and mortality in diabetic patients found that the inverse association was significant for pancreatic and hepatocellular cancer, and nonsignificant for colon, breast, and prostate cancer.
Journal ArticleDOI
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
Jack Cuzick,Ivana Sestak,Bernardo Bonanni,Joseph P. Costantino,Steve Cummings,Andrea Decensi,Mitch Dowsett,John F. Forbes,Leslie G. Ford,Andrea Z. LaCroix,John L. Mershon,Bruce H. Mitlak,Trevor J. Powles,Umberto Veronesi,Victor G. Vogel,D. Lawrence Wickerham +15 more
TL;DR: For all SERMs, incidence of invasive oestrogen (ER)-positive breast cancer was reduced both during treatment and for at least 5 years after completion.
Journal ArticleDOI
Metformin and Cancer Risk and Mortality: A Systematic Review and Meta-Analysis taking into account Biases and Confounders
Sara Gandini,Matteo Puntoni,Brandy M. Heckman-Stoddard,Barbara K. Dunn,Leslie G. Ford,Andrea Decensi,Eva Szabo +6 more
TL;DR: The results show that metformin may reduce cancer incidence and mortality in patients with diabetes However, the reduction seems to be of modest magnitude and not affecting all populations equally.
Journal ArticleDOI
Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline
Kala Visvanathan,Patricia Hurley,Elissa T. Bantug,Powel H. Brown,Nananda F. Col,Jack Cuzick,Nancy E. Davidson,Andrea Decensi,Carol J. Fabian,Leslie G. Ford,Judy Garber,Maria C. Katapodi,Barnett S. Kramer,Monica Morrow,Barbara A. Parker,Carolyn D. Runowicz,Victor G. Vogel,James L. Wade,Scott M. Lippman +18 more
TL;DR: A systematic review of randomized controlled trials and meta-analyses published from June 2007 through June 2012 found six chemoprevention agents were identified and tamoxifen should be discussed as an option to reduce the risk of estrogen receptor -positive BC.
Journal ArticleDOI
Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial
Savino Bruno,Patrick Maisonneuve,Paola Castellana,Nicole Rotmensz,Sonia Rossi,Marco Maggioni,Marcello Persico,Alberto Colombo,Franco Monasterolo,Donata Casadei-Giunchi,Franco Desiderio,Tommaso Stroffolini,Virgilio Sacchini,Andrea Decensi,Umberto Veronesi +14 more
TL;DR: Tamoxifen was associated with higher risk of development of non-alcoholic steatohepatitis only in overweight and obese women with features of metabolic syndrome, but the disease after 10 years of follow up seems to be indolent.